Anixa Biosciences (ANIX) Receivables - Net (2012 - 2026)

Anixa Biosciences' (ANIX) quarterly Receivables - Net came in at $56000.0 in Q2 2026, down 67.63% on a QoQ basis from $173000.0 in Q4 2024.

Anixa Biosciences (ANIX) Receivables - Net (2012 - 2026) Analysis & Trends

Anixa Biosciences (ANIX) has 12 years of Receivables - Net data on file, last reported at $56000.0 in Q2 2026.

Quarterly Receivables - Net changed N/A year-over-year to $56000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $56000.0 (changed N/A YoY) and the FY2024 annual result came in at $173000.0, down 35.93% from the prior year.
Receivables - Net retreated to $56000.0 in Q2 2026, from $173000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $410000.0 in Q3 2024 to a low of $46000.0 in Q4 2022.
A 4-year average of $230100.0 and a median of $237000.0 in 2023 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2023 — Receivables - Net jumped 486.96% — and 2024, when it plunged 35.93%.
Tracing ANIX's Receivables - Net over 4 years: stood at $46000.0 in 2022, then jumped by 486.96% to $270000.0 in 2023, then sank by 35.93% to $173000.0 in 2024, then slumped by 67.63% to $56000.0 in 2026.
The last three Receivables - Net figures came in at $56000.0 (Q2 2026), $173000.0 (Q4 2024), and $410000.0 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-

Download Data